Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Low Dose Ambrisentan in Healthy Adults
NCT04095286Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ambrisentan in pulmonary hypertension (PH) (6 arms), sponsored by GSK. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Time to Cmax at 72 hours and 4 more. Started Sep 2019; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT04095286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04095286.